News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Novo Nordisk A/S Diabetes Drug Liraglutide Helped Obese Lose More Weight Than Roche Holding AG’s Xenical
October 23, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Novo Nordisk A/S’s diabetes drug liraglutide helped overweight, healthy volunteers lose significantly more weight and cut their blood pressure more than Roche Holding AG’s obesity treatment Xenical, a study found.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Novo Nordisk
MORE ON THIS TOPIC
Alzheimer’s disease
Roche Is Back in Alzheimer’s as Latest Antibody Clears Amyloid Plaques
December 2, 2025
·
2 min read
·
Tristan Manalac
PARTNERED WITH VIVA BIOTECH
Building the Next Generation of Biologics: Inside the Future of Protein Engineering
December 1, 2025
·
9 min read
·
BioSpace Insights
FDA
Are Animals Out? How NAMs Are Changing the Rules of the Game
November 26, 2025
·
7 min read
·
BioSpace Insights
Obesity
Novo Bounces Back With ‘Competitive’ Mid-Stage Weight Loss Data for Amycretin
November 25, 2025
·
2 min read
·
Tristan Manalac